XtalPi, an American-Chinese biotech firm that focuses on AI-assisted drug discovery, has raised a $319 million round C from a slate of enthusiastic investors led by SoftBank's Vision Fund. XtalPi works with major pharmaceutical companies like Pfizer that need to identify promising new drug-like molecules and learn as much about them as possible. This company, founded in 2014, purports to offer extremely low-level simulation and prediction of target molecules, both simulating the physics at atomic levels and doing the more traditional data science work that eliminates dead ends and points towards more fruitful avenues for investigation.
Comments
Post a Comment